StockData

Iridex vs Lensar

IRIX and LNSR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IRIX and LNSR compare

Lensar is the larger company, worth 5.1 times as much as Iridex ($61.4M against $12.1M).

Iridex grew revenue faster over the last twelve months (3.7% versus 1.6% for Lensar).

Lensar keeps more of each dollar of sales as profit, with a net margin of 56.1% compared with −6.9% at Iridex.

Iridex scores higher on the StockData Score (8 against 7 for Lensar), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIRIXLNSR
Size and price
Market cap$12.1M$61.4M
Share price$0.690$5.00
Change, 1 year−27.7%−52.0%
Change, 5 years−91.0%−29.6%
Beta (5Y)0.930.59
Employees93150
StockData Score
Total score8 (better)7
Valuation score11
Growth score02 (better)
Performance score22
Health score5 (better)2
Dividend score00
Valuation
P/S0.2× (better)1.0×
P/B3.3× (better)5.6×
FCF yield−16.5%–
Fair value–$5.93
Margin of safety–15.7%
Growth
Revenue growth (TTM)3.7% (better)1.6%
Revenue growth, 5Y average7.7%17.2% (better)
Profitability
Gross margin35.9%52.0% (better)
Operating margin−5.4%−3.3% (better)
Net margin−6.9%56.1% (better)
FCF margin−3.9%–
Return on equity−73.1%–
Financial health
Debt / equity0.000.17 (better)
Current ratio1.822.25 (better)
Altman Z-score−2.50−0.86 (better)
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions12.4%36.0%
Held by insiders76.1%–
Insider net buying, 12 months$536K–
Short interest, % of float0.94%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.